TR201903199T4 - Bir yağ asidiyle kaplı bir beta agonistin kristal mikropartikülleri. - Google Patents
Bir yağ asidiyle kaplı bir beta agonistin kristal mikropartikülleri. Download PDFInfo
- Publication number
- TR201903199T4 TR201903199T4 TR2019/03199T TR201903199T TR201903199T4 TR 201903199 T4 TR201903199 T4 TR 201903199T4 TR 2019/03199 T TR2019/03199 T TR 2019/03199T TR 201903199 T TR201903199 T TR 201903199T TR 201903199 T4 TR201903199 T4 TR 201903199T4
- Authority
- TR
- Turkey
- Prior art keywords
- fatty acid
- beta agonist
- crystalline microparticles
- coated
- agonist coated
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title abstract 2
- 229940125388 beta agonist Drugs 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Buluş, solunum yolu hastalıklarının tedavisi için inhalasyon yoluyla uygulanacak formülasyonlarda kullanıma uygun bir beta2-agonisti içeren talep edilen kristal mikropartiküller ile ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11184687 | 2011-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201903199T4 true TR201903199T4 (tr) | 2019-03-21 |
Family
ID=47115785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/03199T TR201903199T4 (tr) | 2011-10-11 | 2012-10-09 | Bir yağ asidiyle kaplı bir beta agonistin kristal mikropartikülleri. |
Country Status (16)
Country | Link |
---|---|
US (3) | US20130089617A1 (tr) |
EP (1) | EP2765994B1 (tr) |
KR (1) | KR102017915B1 (tr) |
CN (1) | CN103874483B (tr) |
AR (1) | AR088295A1 (tr) |
BR (1) | BR112014008114B1 (tr) |
CA (1) | CA2850084C (tr) |
DK (1) | DK2765994T3 (tr) |
ES (1) | ES2704465T3 (tr) |
HU (1) | HUE042556T2 (tr) |
PL (1) | PL2765994T3 (tr) |
RU (1) | RU2629085C2 (tr) |
SI (1) | SI2765994T1 (tr) |
TR (1) | TR201903199T4 (tr) |
TW (1) | TWI597072B (tr) |
WO (1) | WO2013053696A1 (tr) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54163101A (en) * | 1978-06-14 | 1979-12-25 | Toray Industries | Nonnwaterrrequiring flat printing plate material* and printing plate |
DE2901335A1 (de) * | 1979-01-15 | 1980-07-31 | Basf Ag | Verfahren zur abtrennung von hydrophoben organischen fluessigkeiten aus wasser |
GB8921222D0 (en) * | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
GB9024366D0 (en) | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US20040013611A1 (en) | 1991-12-18 | 2004-01-22 | Minnesota Mining And Manufacturing Company, Now 3M Company | Suspension aerosol formulations |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
EP1169019B1 (en) | 1999-04-14 | 2003-02-26 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
IT1308286B1 (it) * | 1999-06-15 | 2001-12-10 | Leonardo Masotti | Sorgenti e ricevitori ottici estesi continui e barriere otticheutilizzanti dette sorgenti e detti ricevitori |
AU2002234476B2 (en) | 2001-03-30 | 2006-04-27 | Jagotec Ag | Medical aerosol formulations |
AR036358A1 (es) * | 2001-08-28 | 2004-09-01 | Schering Corp | Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma |
SE0200313D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel process |
US7008644B2 (en) * | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
EP1386630B1 (en) | 2002-07-31 | 2006-05-17 | CHIESI FARMACEUTICI S.p.A. | Powder inhaler |
US20060009410A1 (en) | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
GB0426301D0 (en) | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
US8337815B2 (en) | 2004-12-23 | 2012-12-25 | Discovery Laboratories, Inc. | Pulmonary surfactant formulations |
WO2007008427A2 (en) * | 2005-07-08 | 2007-01-18 | Xemplar Pharmaceuticals, Llc | Aerosol compositions and methods |
TW200744612A (en) | 2005-08-26 | 2007-12-16 | Astrazeneca Ab | New combination |
DE102006053886A1 (de) * | 2006-11-14 | 2008-05-15 | Henkel Kgaa | Rückstandsarmer kosmetischer oder dermatologischer Stift auf Basis einer Öl-in-Wasser-Dispersion/Emulsion III |
WO2008152398A2 (en) | 2007-06-14 | 2008-12-18 | Cipla Limited | Formulations for inhalation |
EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
MX2011000410A (es) * | 2008-07-18 | 2011-03-24 | Prosonix Ltd | Proceso para mejorar la cristalinidad de particulas de fluticasona. |
UA113832C2 (xx) * | 2009-12-23 | 2017-03-27 | Комбінаційна терапія для хозл |
-
2012
- 2012-10-09 CA CA2850084A patent/CA2850084C/en active Active
- 2012-10-09 DK DK12780116.5T patent/DK2765994T3/en active
- 2012-10-09 WO PCT/EP2012/069943 patent/WO2013053696A1/en active Application Filing
- 2012-10-09 EP EP12780116.5A patent/EP2765994B1/en active Active
- 2012-10-09 TR TR2019/03199T patent/TR201903199T4/tr unknown
- 2012-10-09 SI SI201231518T patent/SI2765994T1/sl unknown
- 2012-10-09 PL PL12780116T patent/PL2765994T3/pl unknown
- 2012-10-09 CN CN201280049928.8A patent/CN103874483B/zh active Active
- 2012-10-09 HU HUE12780116A patent/HUE042556T2/hu unknown
- 2012-10-09 RU RU2014114014A patent/RU2629085C2/ru active
- 2012-10-09 KR KR1020147009268A patent/KR102017915B1/ko active IP Right Grant
- 2012-10-09 TW TW101137245A patent/TWI597072B/zh active
- 2012-10-09 BR BR112014008114-0A patent/BR112014008114B1/pt active IP Right Grant
- 2012-10-09 ES ES12780116T patent/ES2704465T3/es active Active
- 2012-10-10 AR ARP120103779A patent/AR088295A1/es not_active Application Discontinuation
- 2012-10-11 US US13/649,336 patent/US20130089617A1/en not_active Abandoned
-
2016
- 2016-05-12 US US15/152,835 patent/US10993916B2/en active Active
-
2020
- 2020-01-09 US US16/738,231 patent/US20200138724A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2765994B1 (en) | 2018-12-05 |
EP2765994A1 (en) | 2014-08-20 |
KR20140084025A (ko) | 2014-07-04 |
US10993916B2 (en) | 2021-05-04 |
BR112014008114A2 (pt) | 2017-06-13 |
WO2013053696A1 (en) | 2013-04-18 |
PL2765994T3 (pl) | 2019-09-30 |
RU2014114014A (ru) | 2015-11-20 |
US20160324792A1 (en) | 2016-11-10 |
CA2850084C (en) | 2020-07-07 |
ES2704465T3 (es) | 2019-03-18 |
TW201323015A (zh) | 2013-06-16 |
AR088295A1 (es) | 2014-05-21 |
CN103874483A (zh) | 2014-06-18 |
RU2629085C2 (ru) | 2017-08-24 |
KR102017915B1 (ko) | 2019-09-03 |
US20200138724A1 (en) | 2020-05-07 |
DK2765994T3 (en) | 2019-03-04 |
TWI597072B (zh) | 2017-09-01 |
SI2765994T1 (sl) | 2019-02-28 |
CN103874483B (zh) | 2017-09-12 |
BR112014008114B1 (pt) | 2022-07-26 |
CA2850084A1 (en) | 2013-04-18 |
HUE042556T2 (hu) | 2019-07-29 |
US20130089617A1 (en) | 2013-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216173A1 (zh) | -芳基取代的和 -雜芳基取代的 -羥基吡啶- -基-羰基氨基-鏈烷酸及其衍生物和其鹽,以及用相應 -羥基吡啶甲酸的衍生物進行製備的方法 | |
HK1201260A1 (en) | New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists gpr40 | |
EP2827869A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO | |
AR094204A1 (es) | Composiciones para el cuidado oral que contienen haluros de acido amino | |
CO6930363A2 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
UA114087C2 (xx) | Похідні піридину | |
UY34811A (es) | Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1 | |
SG195086A1 (en) | Compounds containing hydrido-tricyano-borate anions | |
JO3154B1 (ar) | عوامل مضادة لـ trpv4 | |
MY168300A (en) | Pharmaceutical Composition for Inhalation | |
SMT201600341B (it) | Soluzione per somministrazione orale | |
MY168396A (en) | Smoking article comprising menthol | |
EA201400165A1 (ru) | Частицы на основе полиакрилата, которые содержат активное соединение | |
HK1197230A1 (en) | Epoxyeicosatrienoic acid analogs and methods of making and using the same | |
MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
IN2014DN01629A (tr) | ||
MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
ECSP13012366A (es) | Procedimiento de preparación de la sal de l-arginina de perindoprilo | |
MX347541B (es) | Analogos de acido sialico. | |
TN2013000425A1 (en) | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists | |
CO6801771A2 (es) | Composición oral que comprende sodio divalproexy proceso para preparar la misma | |
LT2704698T (lt) | Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui |